BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32299769)

  • 1. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
    Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
    Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
    Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase.
    Liu J; Hancock JG; Moreno AC; Wang Z; Boffa DJ; Detterbeck FC; Kim AW
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):596-601. PubMed ID: 25890936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm.
    Sandler BJ; Wang Z; Hancock JG; Boffa DJ; Detterbeck FC; Kim AW
    Ann Surg Oncol; 2016 Feb; 23(2):638-45. PubMed ID: 26474557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older.
    Driessen E; Detillon D; Bootsma G; De Ruysscher D; Veen E; Aarts M; Janssen-Heijnen M
    J Geriatr Oncol; 2019 Jul; 10(4):547-554. PubMed ID: 30876833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
    Grosu HB; Manzanera A; Shivakumar S; Sun S; Noguras Gonzalez G; Ost DE
    Lung Cancer; 2020 Feb; 140():55-58. PubMed ID: 31865279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
    J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number.
    Wang S; Ma Z; Yang X; Wang Y; Xu Y; Xia W; Chen R; Qiu M; Jiang F; Yin R; Xu L; Xu K
    Radiat Oncol; 2017 Dec; 12(1):207. PubMed ID: 29284511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
    Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
    Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.